drugset / Trial / NCT01518036

Use of Somatropin in Turner Syndrome

NCT01518036

Phase 3 Completed 57 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to study the dose-response relationship and effect of somatropin (Norditropin®) on final height in girls with Turner Syndrome.

Timeline

Start
1987-09-14
Primary completion
2004-04-11
Completion
2004-04-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic 2.9 unknown Subcutaneous
Subject Somatropin Protein / enzyme biologic 4.3 unknown Subcutaneous

Indications